Nisha Rajagopal, Ph.D.

Affiliations: 
2013 Bioinformatics and System Biology University of California, San Diego, La Jolla, CA 
Area:
Inference of gene regulatory networks and determination of protein specificity
Google:
"Nisha Rajagopal"
Mean distance: 9.94
 
SNBCP

Parents

Sign in to add mentor
Wei Wang grad student 2013 UCSD
 (Navigating the Human Epigenome through Random Forests.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Hu S, Marineau JJ, Rajagopal N, et al. (2019) Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Research
Hu S, Marineau J, Hamman K, et al. (2019) Abstract 4421: SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo Cancer Research. 79: 4421-4421
Ke N, Johannessen L, Rajagopal N, et al. (2019) Abstract 4409: Prospective identification of RB pathway alterations predict response to SY-1365, a selective CDK7 inhibitor, in a panel of high-grade serous ovarian cancer (HGSOC) patient derived xenograft (PDX) models Cancer Research. 79: 4409-4409
Johannessen LH, Hu S, Ke N, et al. (2019) Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications Molecular Cancer Therapeutics. 18
Rajagopal N, Hodgson G, Hu S, et al. (2018) Abstract P1-09-08:BCL2L1(BCL-XL) expression and MYC super-enhancer positivity predict sensitivity to the covalent CDK7 inhibitor SY-1365 in triple negative breast cancer (TNBC) cell lines Cancer Research. 78
Konstantinopoulos PA, Hodgson G, Rajagopal N, et al. (2018) Abstract 1525: SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo Cancer Research. 78: 1525-1525
Hu S, Ke N, Ren Y, et al. (2017) Abstract 1151: SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors Cancer Research. 77: 1151-1151
Hashimoto TB, Sherwood R, Kang DD, et al. (2016) A synergistic DNA logic predicts genome-wide chromatin accessibility. Genome Research
Rajagopal N, Srinivasan S, Kooshesh K, et al. (2016) High-throughput mapping of regulatory DNA. Nature Biotechnology
Schultz MD, He Y, Whitaker JW, et al. (2015) Corrigendum: Human body epigenome maps reveal noncanonical DNA methylation variation. Nature
See more...